Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2006

View Archived Issues

Valproic acid induces apoptosis in prostate cancer cells

Telbivudine superior to adefovir in chronic hepatitis B

Pooled data allow subgroup analysis of lubiprostone efficacy in constipation

Studies examine celgosivir pharmacokinetics, activity and tolerability

SkyePharma to develop controlled-release formulation of First Horizon's Sular

Repros updates progress of Androxal study

Enrollment slower than expected in Proellex studies

Dyax grants phage display libraries license to Icos for antibody discovery

GeoVax begins studies of HIV/AIDS vaccine

SPA agreement for phase III study of CoFactor

Ramelteon shows potential for circadian phase shifting

ProEthic begins phase III study for PRO-513 for migraines

Orphan drug designation for Talotrexin for ALL

XP-19986 reduces number of reflux episodes in GERD patients

CRx-102 reduces CRP in human inflammatory model

Unusually high placebo response rate causes failure of bicifadine phase III trial

Debiopharm and TcLand sign inlicensing option agreement for sc28AT

Prous Science webcasts AUA Annual Meeting in Atlanta

Tranzyme presents new in vivo data on novel gastrointestinal drug candidates

J&J develops novel leukotriene A4 hydrolase inhibitors for IBD

Early studies with alpha4 integrin antagonist T-728 suggest possible use in IBD

Inhibition of PI3K/Akt signaling appears promising to treat prostate cancer

Adenosine A2A receptor antagonist MSX-3 shows activity in parkinsonian motor effects

Vernalis presents preclinical, clinical update on BIIB-014 for Parkinson's disease

New antiinfective agents reported in recent patents

New treatment options for cardiovascular diseases disclosed in recent patent literature

Recent Merz patent discloses novel agents for drug addiction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...